Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats

被引:51
作者
Zhang, HT [1 ]
Zhao, Y
Huang, Y
Deng, CJ
Hopper, AT
De Vivo, M
Rose, GM
O'Donnell, JM
机构
[1] W Virginia Univ, Hlth Sci Ctr, Dept Behav Med, Morgantown, WV 26506 USA
[2] Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA
[3] Mem Pharmaceut Corp, Montvale, NJ 07645 USA
关键词
antidepressant; drug discrimination; behavior; phosphodiesterase; PDE4; inhibitor; forced-swim; DRL; rolipram binding site;
D O I
10.1007/s00213-006-0369-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Phosphodiesterase-4 (PDE4) has two conformation states based on rolipram binding, the high-affinity rolipram binding state (HARBS) and the low-affinity rolipram binding state (LARBS); their functions remain to be fully explained. Objective: Experiments were carried out to determine the roles of the HARBS and LARBS in the mediation of antidepressant-like effects on behavior. Materials and methods: Two animal models sensitive to antidepressant drugs, the forced-swim test (FST), and the differential-reinforcement-of-low-rate (DRL) 72-s operant schedule, were used to examine the antidepressant-like effects of rolipram, CDP840, and piclamilast, PDE4 inhibitors that interact differentially with the HARBS and LARBS, and MEM1018 and MEM1091, two novel PDE4 inhibitors. Drug discrimination vs rolipram and rolipram competition binding assays also were carried out. Results: In the FST, rolipram and piclamilast, both at 0.1 mg/kg, produced an antidepressant-like effect, i.e., reduced immobility and increased swimming, whereas, 1 mg/kg of CDP840 or 0.5 mg/kg of MEM1018 or MEM1091 was required to produce a similar effect. Consistent with this, only rolipram and piclamilast produced antidepressant-like effects in rats under the DRL schedule of reinforcement, as evidenced by decreased response rates and increased reinforcement rates. In addition, in rats trained to discriminate rolipram from its vehicle, only rolipram and piclamilast substituted. Finally, [H-3]rolipram and [H-3]piclamilast binding analysis revealed that CDP840 and the two novel PDE4 inhibitors MEM1018 and MEM1091 exhibited a lower affinity for the HARBS than did rolipram. Conclusion: These results suggest that the HARBS of PDE4 is the primary conformation important for antidepressant-like effects on behavior.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 34 条
[1]   Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor [J].
Asanuma, M ;
Nishibayashi, S ;
Iwata, E ;
Kondo, Y ;
Nakanishi, T ;
Vargas, MG ;
Ogawa, N .
MOLECULAR BRAIN RESEARCH, 1996, 41 (1-2) :210-215
[2]  
BRUCATO FH, 2005, PDE4 INHIBITOR AFFIN
[3]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[4]   Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling [J].
Conti, M ;
Richter, W ;
Mehats, C ;
Livera, G ;
Park, JY ;
Jin, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) :5493-5496
[5]   A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo [J].
Cooper, N ;
Teixeira, MM ;
Warneck, J ;
Miotla, JM ;
Wills, RE ;
Macari, DMT ;
Gristwood, RW ;
Hellewell, PG .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (08) :1863-1871
[6]   Biarylcarboxylic acids and -amides: Inhibition of phosphodiesterase type IV versus [H-3]rolipram binding activity and their relationship to emetic behavior in the ferret [J].
Duplantier, AJ ;
Biggers, MS ;
Chambers, RJ ;
Cheng, JB ;
Cooper, K ;
Damon, DB ;
Eggler, JF ;
Kraus, KG ;
Marfat, A ;
Masamune, H ;
Pillar, JS ;
Shirley, JT ;
Umland, JP ;
Watson, JW .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (01) :120-125
[7]  
Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/bj20021698
[8]  
Jacobitz S, 1996, MOL PHARMACOL, V50, P891
[9]   AUTORADIOGRAPHIC MAPPING OF A SELECTIVE CYCLIC ADENOSINE-MONOPHOSPHATE PHOSPHODIESTERASE IN RAT-BRAIN WITH THE ANTIDEPRESSANT [H-3] ROLIPRAM [J].
KAULEN, P ;
BRUNING, G ;
SCHNEIDER, HH ;
SARTER, M ;
BAUMGARTEN, HG .
BRAIN RESEARCH, 1989, 503 (02) :229-245
[10]  
Li C, 2001, DRUG METAB DISPOS, V29, P232